Literature DB >> 2834257

Role of opiate receptors in the regulation of colonic transit.

P N Kaufman1, B Krevsky, L S Malmud, A H Maurer, M B Somers, J A Siegel, R S Fisher.   

Abstract

The effects of morphine and the opiate antagonist naloxone on human colonic transit were investigated. In a crossover, double-blind fashion, two groups of 6 normal volunteers were studied using colonic transit scintigraphy during the administration of a test drug or control. The test drugs were morphine (0.1 mg/kg every 6 h s.c.) or naloxone (0.8 mg every 6 h s.c.); control was saline (1 ml every 6 h s.c.). Morphine significantly delayed transit in the cecum and ascending colon (p less than 0.05), slowed the progression of the geometric center (p less than 0.01), and decreased the number of bowel movements per 48 h (p less than 0.005). Naloxone accelerated transit in the transverse colon and rectosigmoid colon (p less than 0.05) and accelerated the progression of the geometric center (p less than 0.05), but had no effect on the number of bowel movements per 48 h (p greater than 0.05). These results suggest that narcotic analgesics may cause constipation in part by slowing colonic transit in the proximal colon and by inhibiting defecation. Acceleration of transit by naloxone suggests that endogenous opiate peptides may play an inhibitory role in the regulation of human colonic transit.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2834257     DOI: 10.1016/0016-5085(88)90673-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  43 in total

1.  Effects of mu and kappa opioid receptor agonists and antagonists on contraction of isolated colon strips of rats with cathartic colon.

Authors:  Bao-Hua Liu; Ping Mo; Sheng-Ben Zhang
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

Review 2.  Management of opioid-induced bowel dysfunction in cancer patients.

Authors:  Antonio Cesar Tamayo; Paola Andrea Diaz-Zuluaga
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 3.  New treatment options for chronic constipation: mechanisms, efficacy and safety.

Authors:  Michael Camilleri
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

4.  Effects of naloxegol on whole gut transit in opioid-naïve healthy subjects receiving codeine: A randomized, controlled trial.

Authors:  H Halawi; P Vijayvargiya; I Busciglio; I Oduyebo; D Khemani; M Ryks; D Rhoten; D Burton; L A Szarka; A Acosta; M Camilleri
Journal:  Neurogastroenterol Motil       Date:  2018-02-06       Impact factor: 3.598

5.  Enkephalins modulate inhibitory neuromuscular transmission in circular muscle of human colon via delta-opioid receptors.

Authors:  C H Hoyle; M A Kamm; G Burnstock; J E Lennard-Jones
Journal:  J Physiol       Date:  1990-12       Impact factor: 5.182

6.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 7.  Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach.

Authors:  Spencer Dorn; Anthony Lembo; Filippo Cremonini
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

8.  Control of muscle tone in the human colon.

Authors:  C J Steadman; S F Phillips; M Camilleri; N J Talley; A Haddad; R Hanson
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

9.  Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study.

Authors:  Masanori Mori; Yongli Ji; Santosh Kumar; Takamaru Ashikaga; Steven Ades
Journal:  Int J Clin Oncol       Date:  2016-09-15       Impact factor: 3.402

10.  Managing opioid-induced constipation in advanced illness: focus on methylnaltrexone bromide.

Authors:  Katri Elina Clemens; Eberhard Klaschik
Journal:  Ther Clin Risk Manag       Date:  2010-03-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.